Trials / Recruiting
RecruitingNCT04709796
The Use of High Concentration Hyaluronic Acid (HA) Transfer Medium in Repeated Implantation Failure (RIF) Patients
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- Sponsor
- University Hospital, Ghent · Academic / Other
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This is a pilot study with the aim to investigate the beneficial effect of bicarbonate buffered medium containing hyaluronan and recombinant human albumin (EmbryoGlue®, Vitrolife) in patients with documented repeated implantation failure on live birth per randomized subject as primary endpoint.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EmbryoGlue®, Vitrolife | The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent. |
| DRUG | Conventional Transfer | The control arm is the conventional embryo transfer without Embryo glue medium |
Timeline
- Start date
- 2021-03-03
- Primary completion
- 2024-12-31
- Completion
- 2025-06-30
- First posted
- 2021-01-14
- Last updated
- 2024-04-12
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04709796. Inclusion in this directory is not an endorsement.